23andMe Holding Co.
NASDAQ:ME
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
23andMe Holding Co.
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
